UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 190

Sortiert nach

Proton pump inhibitors increase the risk for hospital-acquired Clostridium difficile infection in critically ill patients

Critical care (London, England), 2014-12, Vol.18 (6), p.714-714, Article 714

2014

Link zum Volltext

Verfügbarkeit prüfen

Anaphylaxis: Underdiagnosed, Underreported, and Undertreated

The American journal of medicine, 2014, Vol.127 (1), p.S1-S5

2014

Link zum Volltext

Verfügbarkeit prüfen

Joint effects of advancing age and number of potentially inappropriate medication classes on risk of falls in Medicare enrollees

BMC geriatrics, 2019-07, Vol.19 (1), p.194-194, Article 194

2019

Link zum Volltext

Verfügbarkeit prüfen

Diagnosis and Treatment of ADHD in the United States: Update by Gender and Race

Journal of attention disorders, 2020-01, Vol.24 (1), p.10-19

2020

Link zum Volltext

Verfügbarkeit prüfen

All-Cause and Drug-Related Medical Events Associated with Overuse of Gabapentin and/or Opioid Medications: A Retrospective Cohort Analysis of a Commercially Insured US Population

Drug safety, 2018-02, Vol.41 (2), p.213-228

2018

Link zum Volltext

Verfügbarkeit prüfen

Use of power-law analysis to predict abuse or diversion of prescribed medications: proof-of-concept mathematical exploration

BMC research notes, 2018-07, Vol.11 (1), p.523-523, Article 523

2018

Link zum Volltext

Verfügbarkeit prüfen

Effectiveness of a pharmacist–nurse intervention on resolving medication discrepancies for patients transitioning from hospital to home health care

American journal of health-system pharmacy, 2009-11, Vol.66 (22), p.2027-2031

2009

Link zum Volltext

Verfügbarkeit prüfen

Combined Gabapentinoid and Opioid Use

Annals of internal medicine, 2019-06, Vol.170 (12), p.908

2019

Link zum Volltext

Verfügbarkeit prüfen

Trends in prescriptions for antidepressant pharmacotherapy among US children and adolescents diagnosed with depression, 1990 through 2001: An assessment of accordance with treatment recommendations from the American Academy of Child and Adolescent Psychiatry

Clinical therapeutics, 2009-01, Vol.31, p.1478-1487

2009

Link zum Volltext

Verfügbarkeit prüfen

Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance

Risk management and healthcare policy, 2018-01, Vol.11, p.109-116

2018

Link zum Volltext

Verfügbarkeit prüfen

Predictors of Gabapentin Overuse With or Without Concomitant Opioids in a Commercially Insured U.S. Population

Pharmacotherapy, 2018-04, Vol.38 (4), p.436-443

2018

Link zum Volltext

Verfügbarkeit prüfen

Economic Implications of Sleep Disorders

PharmacoEconomics, 2010-11, Vol.28 (11), p.1015-1023

2010

Link zum Volltext

Verfügbarkeit prüfen

Prevalence of Gabapentin Abuse: Comparison with Agents with Known Abuse Potential in a Commercially Insured US Population

Clinical drug investigation, 2017-08, Vol.37 (8), p.763-773

2017

Link zum Volltext

Verfügbarkeit prüfen

Policies to mitigate nonmedical use of prescription medications: how should emerging evidence of gabapentin misuse be addressed?

Expert opinion on drug safety, 2018-05, Vol.17 (5), p.519-523

2018

Link zum Volltext

Verfügbarkeit prüfen

Authors’ Reply to: Tomoyuki Kawada’s Comment on: “All-Cause and Drug-Related Medical Events Associated with Overuse of Gabapentin and/or Opioid Medications: A Retrospective Cohort Analysis of a Commercially Insured US Population

Drug safety, 2018-06, Vol.41 (6), p.643-644

2018

Link zum Volltext

Verfügbarkeit prüfen

National Trends in the Prevalence of Attention-Deficit/Hyperactivity Disorder and the Prescribing of Methylphenidate among School-Age Children: 1990-1995

Clinical pediatrics, 1999-04, Vol.38 (4), p.209-217

1999

Link zum Volltext

Verfügbarkeit prüfen

Use of Proton Pump Inhibitors for the Provision of Stress Ulcer Prophylaxis: Clinical and Economic Consequences

PharmacoEconomics, 2014, Vol.32 (1), p.5-13

2014

Link zum Volltext

Verfügbarkeit prüfen

Quantifying Gabapentin Misuse With Opioids

Primary care companion for CNS disorders, 2019-03, Vol.21 (2)

2019

Link zum Volltext

Verfügbarkeit prüfen

Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice

Therapeutics and clinical risk management, 2017-01, Vol.13, p.957-965

2017

Link zum Volltext

Verfügbarkeit prüfen

Hospital length of stay for children and adolescents diagnosed with depression: is primary payer an influencing factor?

General hospital psychiatry, 2008, Vol.30 (1), p.73-76

2008

Link zum Volltext

Verfügbarkeit prüfen

Issues in adherence to treatment with monoamine oxidase inhibitors and the rate of treatment failure

The journal of clinical psychiatry, 2012, Vol.73 Suppl 1, p.31

2012

Link zum Volltext

Verfügbarkeit prüfen

MAOIs: issues in treatment adherence and rates of treatment failure

The journal of clinical psychiatry, 2013, Vol.74 (1), p.e02

2013

Link zum Volltext

Verfügbarkeit prüfen

Cardiovascular Risk Factors and Provision of Lifestyle Counseling for Diabetes or Prediabetes With Comorbid Obesity: Analysis of Office-Based Physician Visits Made by Patients 20 Years of Age or Older

Diabetes spectrum, 2019-02, Vol.32 (1), p.53-59

2019

Link zum Volltext

Verfügbarkeit prüfen

Concomitant use of opioid medications with triptans or serotonergic antidepressants in US office-based physician visits

Drug, healthcare and patient safety, 2018-01, Vol.10, p.37-43

2018

Link zum Volltext

Verfügbarkeit prüfen

Provision of Lifestyle Counseling and the Prescribing of Pharmacotherapy for Hyperlipidemia Among US Ambulatory Patients: A National Assessment of Office-Based Physician Visits

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2018-02, Vol.18 (1), p.65-71

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 190

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(166)
Mit Volltextzugriff
(162)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(190)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(90)
Science & Technology
(90)
Humans
(76)
Pharmacology & Pharmacy
(56)
Female
(45)
Male
(41)
Biological And Medical Sciences
(37)
Medical Sciences
(36)
Adult
(34)
Middle Aged
(33)
Aged
(28)
Pharmacology. Drug Treatments
(28)
United States
(24)
Adolescent
(18)
Psychology. Psychoanalysis. Psychiatry
(17)
Drug Therapy
(16)
Medicine
(16)
Depression
(15)
Health Care Sciences & Services
(14)
Medicine & Public Health
(14)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Proton pump inhibitors increase the risk for hospital-acquired Clostridium difficile infection in critically ill patients

Anaphylaxis: Underdiagnosed, Underreported, and Undertreated

Joint effects of advancing age and number of potentially inappropriate medication classes on risk of falls in Medicare enrollees

Diagnosis and Treatment of ADHD in the United States: Update by Gender and Race

All-Cause and Drug-Related Medical Events Associated with Overuse of Gabapentin and/or Opioid Medications: A Retrospective Cohort Analysis of a Commercially Insured US Population

Use of power-law analysis to predict abuse or diversion of prescribed medications: proof-of-concept mathematical exploration

Effectiveness of a pharmacist–nurse intervention on resolving medication discrepancies for patients transitioning from hospital to home health care

Combined Gabapentinoid and Opioid Use

Trends in prescriptions for antidepressant pharmacotherapy among US children and adolescents diagnosed with depression, 1990 through 2001: An assessment of accordance with treatment recommendations from the American Academy of Child and Adolescent Psychiatry

Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance

Predictors of Gabapentin Overuse With or Without Concomitant Opioids in a Commercially Insured U.S. Population

Economic Implications of Sleep Disorders

Prevalence of Gabapentin Abuse: Comparison with Agents with Known Abuse Potential in a Commercially Insured US Population

Policies to mitigate nonmedical use of prescription medications: how should emerging evidence of gabapentin misuse be addressed?

Authors’ Reply to: Tomoyuki Kawada’s Comment on: “All-Cause and Drug-Related Medical Events Associated with Overuse of Gabapentin and/or Opioid Medications: A Retrospective Cohort Analysis of a Commercially Insured US Population

National Trends in the Prevalence of Attention-Deficit/Hyperactivity Disorder and the Prescribing of Methylphenidate among School-Age Children: 1990-1995

Use of Proton Pump Inhibitors for the Provision of Stress Ulcer Prophylaxis: Clinical and Economic Consequences

Quantifying Gabapentin Misuse With Opioids

Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice

Hospital length of stay for children and adolescents diagnosed with depression: is primary payer an influencing factor?

Issues in adherence to treatment with monoamine oxidase inhibitors and the rate of treatment failure

MAOIs: issues in treatment adherence and rates of treatment failure

Cardiovascular Risk Factors and Provision of Lifestyle Counseling for Diabetes or Prediabetes With Comorbid Obesity: Analysis of Office-Based Physician Visits Made by Patients 20 Years of Age or Older

Concomitant use of opioid medications with triptans or serotonergic antidepressants in US office-based physician visits

Provision of Lifestyle Counseling and the Prescribing of Pharmacotherapy for Hyperlipidemia Among US Ambulatory Patients: A National Assessment of Office-Based Physician Visits

Suchergebnisse filtern